Stay updated with breaking news from Ionis Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating)‘s stock had its “maintains” rating reaffirmed by investment analysts at VNET Group in a report issued on Thursday, Benzinga reports. Several other equities analysts have also weighed in on the company. SVB Securities cut their target price on Ionis Pharmaceuticals from $34.00 to $27.00 in a report on Thursday, […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) posted its quarterly earnings data on Wednesday. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.13, Briefing.com reports. Ionis Pharmaceuticals had a negative net margin of 45.75% and a negative return on equity of 43.01%. The company had revenue […]
Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, May 3rd. Analysts expect the company to announce earnings of ($1.00) per share for the quarter. Ionis Pharmaceuticals has set its FY 2023 guidance at EPS.Individual interested in participating in the company’s earnings conference call […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the […]
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) – Stock analysts at Zacks Research increased their Q1 2023 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, April 19th. Zacks Research analyst K. Shah now forecasts that the company will earn ($1.00) per share […]